These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 29499662)

  • 1. Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
    Ye SL; Yang J; Bie P; Zhang S; Chen X; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Lv Z
    BMC Cancer; 2018 Mar; 18(1):247. PubMed ID: 29499662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
    Kudo M; Ikeda M; Takayama T; Numata K; Izumi N; Furuse J; Okusaka T; Kadoya M; Yamashita S; Ito Y; Kokudo N
    J Gastroenterol; 2016 Dec; 51(12):1150-1160. PubMed ID: 27106231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
    Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
    Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
    Kim DY; Kim HJ; Han KH; Han SY; Heo J; Woo HY; Um SH; Kim YH; Kweon YO; Lim HY; Yoon JH; Lee WS; Lee BS; Lee HC; Ryoo BY; Yoon SK
    Cancer Res Treat; 2016 Oct; 48(4):1243-1252. PubMed ID: 26910470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
    Ye SL; Chen X; Yang J; Bie P; Zhang S; Liu F; Liu L; Zhou J; Dou K; Hao C; Shao G; Xia Q; Chen Y; Yang J; Deng X; Liu Y; Yuan Y; Fu Z; Nakajima K; Yip CS; Lu Z
    Oncotarget; 2016 Feb; 7(6):6639-48. PubMed ID: 26735891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
    J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
    Lencioni R; Kudo M; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JF; de Guevara LL; Papandreou C; Takayama T; Yoon SK; Nakajima K; Lehr R; Heldner S; Sanyal AJ
    Int J Clin Pract; 2014 May; 68(5):609-17. PubMed ID: 24283303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
    Merchante N; Ibarra S; Revollo B; Rodríguez-Arrondo F; Merino E; Delgado-Fernández M; Montero-Alonso M; Téllez F; Galindo MJ; Rivero-Juárez A; García MA; Mínguez C; Romero-Palacios A; Garcia-Deltoro M; Pineda JA;
    AIDS; 2017 Jan; 31(1):89-95. PubMed ID: 27755109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
    D'Angelo S; Germano D; Zolfino T; Sansonno D; Giannitrapani L; Benedetti A; Montesarchio V; Attili A; Buonadonna A; Barni S; Gasbarrini A; Burlone ME; Cillo U; Marenco S; Villa E; Giovanis P; Proserpio I; Saitta C; Magini G; Cengarle R; Fava G; Cuttone F; Calvani N; Angelico M; Di Costanzo F; Noto A; Poggi G; Marignani M; Cascinu S; Amoroso D; Palmieri V; Massa E; Crocè LS; Picardi A; Tumulo S; Erminero C; Lencioni R; Lorusso V
    Recenti Prog Med; 2015 May; 106(5):217-26. PubMed ID: 25994538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
    Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
    J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of sorafenib in Child-Pugh A patients with unresectable hepatocellular carcinoma.
    Shen A; Tang C; Wang Y; Chen Y; Yan X; Zhang C; Liu R; Wei X; Zhu Y; Zhang H; Wu Z
    J Clin Gastroenterol; 2013; 47(10):871-80. PubMed ID: 24100749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
    Meyer T; Fox R; Ma YT; Ross PJ; James MW; Sturgess R; Stubbs C; Stocken DD; Wall L; Watkinson A; Hacking N; Evans TRJ; Collins P; Hubner RA; Cunningham D; Primrose JN; Johnson PJ; Palmer DH
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):565-575. PubMed ID: 28648803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Saito T; Motoyama T; Suzuki E; Tawada A; Kanai F; Yokosuka O
    Invest New Drugs; 2015 Jun; 33(3):729-39. PubMed ID: 25861764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
    Marrero JA; Kudo M; Venook AP; Ye SL; Bronowicki JP; Chen XP; Dagher L; Furuse J; Geschwind JH; de Guevara LL; Papandreou C; Takayama T; Sanyal AJ; Yoon SK; Nakajima K; Lehr R; Heldner S; Lencioni R
    J Hepatol; 2016 Dec; 65(6):1140-1147. PubMed ID: 27469901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
    Wang W; Bai W; Wang E; Zhao Y; Liu L; Yang M; Cai H; Xia D; Zhang L; Niu J; Yin Z; Zhang Z; Fan D; Xia J; Han G
    Int J Cancer; 2017 Jan; 140(2):390-399. PubMed ID: 27681592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.